Medical Information Only. Always consult your healthcare provider before enrolling in any clinical trial.
NCT02172911 · ClinicalTrials.gov registry record · Phase 1
A Study of INO-3112 DNA Vaccine With Electroporation in Participants With Cervical Cancer
A Phase 1 study, sponsored by Inovio Pharmaceuticals.
- Completed
- Registry status
- Phase 1
- Development phase
- 10
- Enrollment target
NCT02172911 is a Phase 1 study that has completed, run by Inovio Pharmaceuticals. The registered enrollment target is 10 participants.
The verdict
NCT02172911, a Phase 1 study, has completed, sponsored by Inovio Pharmaceuticals.
- COMPLETED
- Registry status
- Phase 1
- Development phase
- 10 participants
- Enrollment target
Study Summary
This is an open-label study to evaluate the safety, tolerability, and immunogenicity of INO-3112 DNA vaccines delivered by electroporation (EP) to female participants with HPV-16 and/or 18-positive cervical carcinoma.
Interventions
- BIOLOGICAL INO-3112
- DEVICE CELLECTRA™-5P
Trial Details
| Field | Value |
|---|---|
| Enrollment Target | 10 participants |
| Start Date | 2014-06-06 |
| Est. Completion | 2017-09-07 |
| Phase | Phase 1 |
Interested in This Trial?
Full Details on ClinicalTrials.gov ↗What the Registry Record Tells You About NCT02172911
The ClinicalTrials.gov registry entry for NCT02172911 describes a study currently listed as completed, categorized as Phase 1. The registered enrollment target is 10 participants, a figure that helps gauge the scale of data the investigators plan to collect. The listed sponsor is Inovio Pharmaceuticals, which has 28 total studies on file at ClinicalTrials.gov.
The record links to 0 conditions, and to 2 interventions - of which INO-3112 is the first listed.
NCT02172911 reports 0 study locations.
Frequently Asked Questions
What is clinical trial NCT02172911 about?
NCT02172911 is a clinical study titled "A Study of INO-3112 DNA Vaccine With Electroporation in Participants With Cervical Cancer". This is an open-label study to evaluate the safety, tolerability, and immunogenicity of INO-3112 DNA vaccines delivered by electroporation (EP) to female participants with HPV-16 and/or 18-positive cervical carcinoma.
What is the current status of trial NCT02172911?
This trial is currently completed. It is a Phase 1 study. The enrollment target is 10 participants. The study started on 2014-06-06. Estimated completion is 2017-09-07.
What interventions are being tested in trial NCT02172911?
The interventions under investigation include: INO-3112 (BIOLOGICAL), CELLECTRA™-5P (DEVICE).
Who is sponsoring clinical trial NCT02172911?
This trial is sponsored by Inovio Pharmaceuticals, which has 28 total clinical trials registered on ClinicalTrials.gov.
Learn More About Clinical Trials
Explore more on PlainTrial
Read our methodology - how this data is sourced, computed, and verified.
Related
Every figure on PlainTrial is rendered directly from the ClinicalTrials.gov registry, no number is typed in by an editor. This page mirrors this trial's own ClinicalTrials.gov registry record, live from the dataset. See our editorial standards & corrections policy, the methodology behind these numbers, or report a data error.